A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

necessitates a REMS program, a “Patient Agreement Form,” and a “Black Box” warning. And it suggests FDA’s actions are well “outside the zone of reasonableness.” It’s unreasonable ...

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Purpose The results of a hospital's initiative to evaluate and improve compliance with federally mandated risk evaluation and mitigation strategies (REMS) are presented. Summary Food and Drug ...

However, Spravato remains restricted under the FDA's REMS program due to its abuse potential. Investors will watch how this regulatory win impacts Johnson & Johnson's pharma segment ahead of earnings.

The growing disproportionate amount of drug spending on such a small subset ... the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Finally, some pharmaceutical manufacturers ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Heart failure may cause symptoms such as: Due to the risk of heart failure, Camzyos is available through a risk evaluation and mitigation strategies (REMS) program only. The FDA requires REMS ...